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Abstract
Adaptive immune responses are initiated when T cells encounter antigen on dendritic cells (DC) in T zones of secondary
lymphoid organs. T zones contain a 3-dimensional scaffold of fibroblastic reticular cells (FRC) but currently it is unclear how
FRC influence T cell activation. Here we report that FRC lines and ex vivo FRC inhibit T cell proliferation but not
differentiation. FRC share this feature with fibroblasts from non-lymphoid tissues as well as mesenchymal stromal cells. We
identified FRC as strong source of nitric oxide (NO) thereby directly dampening T cell expansion as well as reducing the T
cell priming capacity of DC. The expression of inducible nitric oxide synthase (iNOS) was up-regulated in a subset of FRC by
both DC-signals as well as interferon-c produced by primed CD8+ T cells. Importantly, iNOS expression was induced during
viral infection in vivo in both LN FRC and DC. As a consequence, the primary T cell response was found to be exaggerated in
Inos2/2 mice. Our findings highlight that in addition to their established positive roles in T cell responses FRC and DC
cooperate in a negative feedback loop to attenuate T cell expansion during acute inflammation.
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Introduction
Adaptive immune responses are initiated most efficiently within
secondary lymphoid organs (SLO), such as the spleen or lymph
nodes (LN), where pathogens (or foreign antigens) are filtered from
body fluids and presented to recirculating T cells. Typically,
dendritic cells (DC) residing in peripheral tissues capture foreign
antigens and danger signals inducing their maturation, including
up-regulation of the chemokine receptor CCR7 allowing DC to
migrate via lymphatic vessels into the paracortex (T zone) of the
draining SLO. There they present antigen-derived peptides in the
context of surface MHC molecules to thousands of naı¨ve
recirculating T cells. Only the rare antigen-specific T cells become
activated, start secreting cytokines and undergo multiple rounds of
cell division. Finally, they differentiate into effector cells and leave
the LN as a large cohort that migrates specifically to the site of
inflammation [1,2,3,4].
Both in mice and humans, the microenvironment where T cells
encounter DC is spanned by a 3-dimensional (3D) network of T
zone fibroblastic reticular cells (T-FRC or TRC) known to
produce the extracellular matrix scaffold, including microvessels
called conduits [2,4,5,6,7,8,9]. More recently it has become clear
that TRC are not only cells providing a 3D microenvironment but
play an active role in adaptive immunity. They physically guide
lymphocytes during their several hours-long migration across the
T zone by forming a ‘road system’ [2]. TRC also actively recruit
CCR7 expressing T cells and DC into the T zone by constitutively
secreting CCL19 and CCL21 [9,10,11]. These chemokines not
only retain T cells in the T zone but also promote their motility
[12]. Furthermore, incoming and resident DC adhere to TRC as
well as their associated matrix structures [2,4,8]. Finally, TRC are
the major constitutive source of IL-7 in LN and access to LN TRC
is critical for naı¨ve T cell survival [9,13].
As the processes of selection, amplification and differentiation of
antigen-specific T cells all take place within the TRC environment,
it raises the possibility that TRC positively influence these steps.
Several lines of evidence support this hypothesis: First, the TRC
network appears to increase the frequency of DC-T cell encounters
leading to a faster selection of antigen-specific T cells whose
frequency is estimated to be around 1 out of 100’000 T cells for a
given protein antigen. Both physical and chemical guidance cues
provided by TRC are thought to contribute to this effect [2,4].
Second, the homeostatic chemokines CCL19 and CCL21 act as co-
stimulatory signals for T cell activation and proliferation in vitro
[14,15]. These chemokines also increase DC maturation and
function (reviewed in [16]). Third, IL-7 enhances T cell responses to
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viral infections in vivo [17,18]. Together, these observations have
strengthened the notion that TRC help in the induction of T cell
responses by accelerating T cell priming and expansion.
However, recent reports have suggested that TRC may also
negatively regulate T cell responses. TRC were shown to express
the inhibitory programmed death ligand 1 (PD-L1) thereby
reducing CD8 T cell mediated pathology [19]. TRC also express
self-antigens in the context of MHC class I thereby promoting
CD8+ T cell tolerance [20,21] (reviewed in [22,23]). In addition,
stromal cells isolated from neonatal or adult spleen were shown to
induce over 1–2 weeks the development of DC that inhibit T cell
proliferation in vitro. The spleen contains many stromal cell subsets
and the precise identity of the cells used as well as their localization
relative to DC and T cells has remained unclear [24,25].
Together, these observations indicate that lymphoid tissue stromal
cells may also inhibit T cell responses.
Currently, the exact role of LN TRC in T cell activation and
differentiation is not known. This is in part due to the difficulty of
isolating sufficient numbers of TRC for in vitro experiments and the
lack of appropriate tools to investigate TRC in vivo. Here we used a
combination of in vitro and in vivo approaches to study the effect of
TRC on CD8+ T cell priming by antigen-pulsed DC. We
demonstrate that TRC diminish T cell expansion by releasing
NO. They share this property with a subset of DC. We show that
NO production by TRC and DC is strongly dependent on
cytokines from activated T cells suggesting a negative feedback
loop once T cell priming has started. Our in vivo findings using
Inos2/2 mice indicate that TRC and DC limit the speed of T cell
expansion possibly to ensure organ functionality during the early
phase of acute lymph node swelling.
Results
Lymph node TRC dampen T cell expansion
To dissect the role of TRC in T cell activation and
differentiation, we initially adopted a reductionist approach: T
cells were co-cultured with antigen-pulsed bone-marrow derived
DC (BM-DC), either in the presence or absence of TRC. Given
the difficulties in isolating pure TRC populations, several
independent TRC cell lines were established from peripheral
lymph nodes (pLN=pool of inguinal, axillary and brachial LN) of
C57BL/6 wild-type (WT) mice (referred to as ‘pLN1’ and ‘pLN2’)
or GFP-expressing mice (‘GFP-pLN’). All these lines showed
typical fibroblastic morphology and a uniform surface marker
expression pattern comparable to ex vivo isolated TRC (Fig. S1 and
data not shown). In contrast to ex vivo TRC [9] cell lines expressed
only low levels of Ccl19, Ccl21 and Il7 transcripts. To circumvent
this caveat, initial experiments included exogenously added
CCL19, CCL21 and IL-7 protein with no difference in the
outcome (data not shown).
To study T cell priming CD45.1+ congenic ovalbumin (OVA)-
specific OT-I T cell receptor (TCR) transgenic CD8+ T cells were
labeled with the proliferation dye carboxyfluorescein succinimidyl
ester (CFSE), mixed with unspecific WT T cells (CD45.2+) in a
ratio of 1:50, and cultured together with antigen-pulsed BM-DC
on top of an adherent layer of the TRC line. TRC were previously
irradiated to limit their proliferation and nutrient consumption.
Surprisingly, the total OT-I cell number was strongly decreased in
presence of the TRC line pLN2 (Fig. 1A). Using CFSE dilution to
measure T cell proliferation, both the percentage and number of
dividing OT-I T cells were strongly reduced in the presence of
pLN2 (Fig. 1B). The increase in cell size (FSC) and CD44
expression (Fig. 1C) as well as the loss of CD62L expression
(Fig. 1D) occurred in presence of TRC but to a reduced extent.
The co-cultures were supplemented with IL-7 and IL-2, so a lack
of known pro-survival factors for naı¨ve and activated T cells is
unlikely to be the cause. In line with that, the number of naı¨ve,
undivided OT-I T cells was not affected by the TRC presence, nor
was the up-regulation of the high-affinity receptor chain for IL-2,
CD25, on dividing T cells (Fig. 1E). Importantly, several other
fibroblast lines established independently from LN and spleen [26]
not only shared the same surface phenotype (Fig. S1) but also the
inhibitory effect on T cell expansion with a reduction in
proliferating OT-I T cell numbers of 60–90% (Fig. 1F). Impor-
tantly, primary TRC isolated from naı¨ve pLN limited T cell
expansion at least as strongly as TRC lines (Fig. 1G). Even TRC
isolated from pLN of mice immunized 3 days earlier with NP-
CGG in Montanide adjuvant maintained these inhibitory
properties (Fig. 1G). Next, we examined the effect of TRC on
CD8+ T cell differentiation. OT-I T cells primed in presence of
TRC expressed intracellular interferon gamma (IFNc) protein
(Fig. 2A) and killed target cells (Fig. 2B), although with markedly
reduced efficiency (Fig. 2B). Together these results demonstrate
that the presence of TRC during T cell activation diminishes the
expansion or survival of CD8+ T cells and to a lesser extent their
differentiation into effector cells.
Fibroblasts from non-lymphoid organs also attenuate T
cell proliferation
It has been reported that murine and human fibroblasts can
have anti-proliferative effects on activated T cells, similar to
mesenchymal stem cells (MSC) and certain tumor lines
[27,28,29,30,31]. Therefore we tested in our system the inhibitory
potential of several fibroblastic cell lines established de novo from
different non-lymphoid organs, as well as their ex vivo equivalents
(CD452CD352CD312EpCAM2gp38+; see Fig. S2), and com-
pared them to our pLN2 line. In addition, epithelial-like cells from
the epidermis and kidney, a MSC line and two tumor cell lines
(MC38 colon carcinoma and B16-F10 melanoma) were tested. All
cell lines inhibited OT-1 T cell proliferation to an extent
comparable with pLN2 (Fig. 3 A–D), highlighting that inhibition
of T cell expansion is a property common to many cell types,
including fibroblasts from various non-lymphoid organs.
TRC directly inhibit T cell proliferation and render DC less
stimulatory
MSC have been shown to inhibit T cell proliferation by
intracellular expression of enzymes such as indoleamine 2,3-
dioxygenase (IDO) and arginase-1, surface expression of PD-L1,
or by secretion of molecules like NO, prostaglandin E2 (PGE2), IL-
10 and TGFb(reviewed in [30,31]). The proposed pathways
included direct inhibition of T cell proliferation or conversion of
DC to a non-stimulatory or suppressive phenotype (reviewed in
[31,32]). To examine whether TRC can directly interfere with T
cell proliferation pLN2 were co-cultured with anti-CD3/CD28
bead-stimulated T cells. Clearly, TRC diminished the number of
dividing T cells but the inhibitory effect was only half of what we
had observed in the BM-DC-induced T cell activation assay
(Fig. 4A). Next, potential effects of TRC on the stimulatory
capacity of antigen-pulsed BM-DC were investigated by co-
culturing first pLN2 with BM-DC before incubating these ‘TRC-
conditioned’ BM-DC alone with T cells. The capacity to stimulate
T cell proliferation was reduced by half in conditioned relative to
unconditioned BM-DC (Fig. 4B). Together these results indicate
that TRC limit T cell expansion in two additive ways, by making
DC less immunogenic and by directly inhibiting T cell
proliferation or survival.
Lymph Node Fibroblasts Limit T Cell Expansion
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Figure 1. TRC dampen the expansion of antigen-specific CD8+ T cells. Flow cytometric analysis of T cell activation: CFSE-labeled OT-I T cells
were mixed in a ratio of 1:50 with WT T cells (50% CFSE-labeled) and cultured with LPS-activated and OVA-peptide pulsed BM-DC. The assay was
performed without stromal cells (‘no stroma’) or in the presence of TRC from distinct sources (1:1:200 ratio of TRC to BM-DC, and to T cells). (A) Total
OT-I numbers on day 2, 3 and 4 in absence or presence of the pLN2 TRC line. (B) Proliferation of OT-I (black) or polyclonal T cells (gray) as assessed by
CFSE dilution on day 3 or 4 with or without pLN2. Histograms (left) show the percentage (6 standard deviation) of divided OT-I cells and bar graphs
the absolute OT-I cell numbers per CFSE dilution peak (right). (C) Dot plots (left) show CFSE dilution versus cell size (FSC) or CD44 expression of OT-I T
cells after 3 days. Bar graphs (right) indicate the median FSC values or fluorescence intensity. (D) Histograms show CD62L expression and bar graphs
the percentage of CD62Llow OT-I T cells. (E) As c, but showing CD25 expression on OT-I T cells after 4 days of co-culture with or without pLN2. (F,G)
Bar graphs show the percentage inhibition of OT-I T cell proliferation as based on the proliferating OT-I cell numbers after 3 days of co-culture with
different TRC lines (F) or ex vivo isolated and enriched TRC (G). The latter are derived from pLN of unmanipulated B6 mice or from mice s.c. injected
with NP-CGG/Montanide 3 days prior to the TRC harvest (‘activated TRC’). Different symbols indicate different experiments. Data are representative of
.10 (A–D), 3 (E,G), 2–3 (F) experiments; different symbols indicate different experiments. * P,0.05, ** P,0.01, *** P,0.001, P-values relate to ‘no
stroma’ controls.
doi:10.1371/journal.pone.0027618.g001
Lymph Node Fibroblasts Limit T Cell Expansion
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TRC limit T cell expansion by producing NO
To gain insight into the nature of the TRC-derived inhibitory
factor T cells and BM-DC were either separated from the pLN2
by a permeable-membrane (transwell) or simply incubated with
supernatant (SN) from pLN2. Both settings led to a decrease in T
cell expansion, but this was smaller than in co-cultures where all
the three cell types are intermingled (Fig. 5A). These results
suggest a role for either a soluble factor which acts only efficiently
at short distance, or for at least two inhibitory factors, one being
soluble and the other being cell-cell contact dependent. It also
argues against a role for TRC in presenting antigen to T cells and
thereby inhibiting T cell proliferation.
To identify the molecules responsible for suppressing T cell
expansion in our assay several candidates or their synthesis
pathway were blocked, including PD-L1, TGFb, IL-10, IDO and
arginase-1 but none of them neutralized the TRC-mediated
inhibition (Fig. S3). However, blocking the enzymatic activity of
Figure 2. CD8+ T cells primed in presence of TRC still produce
IFNc and kill target cells. The T cell activation assay (see legend of
Fig. 1) was performed without stroma (‘no stroma’) or in presence of the
pLN2 TRC line for 4 days followed by flow cytometric analysis of OT-I T
cell effector function. (A) Dot plots (left) show intracellular IFNc
deposition versus CFSE dilution in OT-I T cells after in vitro re-
stimulation with 1 mM SIINFEKL peptide in presence of brefeldin A. The
right panel shows the median fluorescence intensity of IFNc expression
in OT-I T cells. (B) The cytotoxic capacity of OT-I T cells was assessed by
co-incubating OT-I T cells ( = effector cells, E) from the T cell activation
assay in the indicated E:T ratios with SIINFEKL-pulsed-eFluor670high-
labeled splenocytes ( = target cells, T) mixed 1:1 with unpulsed-
eFluor670low-labeled splenocytes ( = internal control). After overnight
culture the percentage of eFluor670high versus eFluor670low spleno-
cytes was analyzed and plotted as histograms. Indicated as percentage
is the survival index for the target cells, as based on the ratio of peptide-
pulsed eFluor670high relative to unpulsed eFluor670low cells (6 standard
deviation). (A, B): n = 3, representative of 3 independent experiments.
* P,0.05, ** P,0.01, *** P,0.001, P-values are relative to the
corresponding ‘no stroma’ control.
doi:10.1371/journal.pone.0027618.g002
Figure 3. Stromal cells from various non-lymphoid organs
decrease antigen-specific T cell proliferation. The T cell activation
assay (see legend of Fig. 1) was performed in presence of either stromal
cell lines (A,B,D) or ex vivo isolated stromal cells (C). OT-I T cells co-
cultured for 3 days were analyzed for CFSE dilution using flow cytometry.
Representative histograms of CFSE dilution (left panel) and the number
of proliferating OT-I cells as percentage inhibition are presented (right
panel, as in Fig. 1). Shown are assays with a (A) mouse embryonic
fibroblast line (MEF) and lung fibroblast line, (B) lines derived from
different non-lymphoid organs (dermis, heart, femoral muscle, kidney),
(C) ex vivo isolated adherent cells from the dermis, epidermis or kidney,
(D) Mesenchymal stem/stromal cell (MSC) line and the tumor cell lines
B16-F10 (melanoma) and MC-38 (colon carcinoma). (A–D) n$3,
representative for $2 experiments. Different symbols indicate different
experiments. * P,0.05, ** P,0.01, *** P,0.001, if not indicated otherwise
p-values are relative to ‘no stroma’. The dotted line indicates the
inhibition observed by pLN2 cells within the same experiment.
doi:10.1371/journal.pone.0027618.g003
Lymph Node Fibroblasts Limit T Cell Expansion
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iNOS (NOS2) or cyclooxygenase (Cox) 21 and 22 partially
rescued T cell proliferation with the effects of the two
pharmacological inhibitors used being partially additive (Fig. 5B).
This result demonstrates that iNOS-dependent NO and Cox-1/2
dependent factors are responsible for most of the inhibitory effect
observed. We focused our attention on iNOS as transcripts for Inos
but not Cox2 were enhanced in stimulated TRC (as shown later).
Strikingly, Inos2/2 TRC had lost all suppressive activity and
showed even an enhancement of T cell proliferation, in contrast to
the inhibitor 1400W that partially abolished the suppressive effect
of ex vivo WT TRC (Fig. 5C), reminiscent of the effects seen for the
pLN2 line (Fig. 5B). To show directly the expression of iNOS
protein in TRC and assess the frequency of iNOS-expressing cells,
antibodies to iNOS were used in immunofluorescence microscopy.
Surprisingly, iNOS protein could only be detected in pLN2 co-
cultures with BM-DC and activated T cells. However, iNOS was
only detected in a small fraction of gp38+ TRC (Fig. 5D).
Occasionally, iNOS protein staining was observed in BM-DC-like
cells (gp382) but never in lymphocytes (not shown). These
experiments establish that TRC are a source of iNOS that inhibits
T cell proliferation. They also demonstrate that the inhibitory
activity of TRC on T cell expansion is not due to metabolic effects
of co-culture.
As a readout of iNOS activity, we measured extracellular nitrite
levels in the SN. In absence of TRC the SN of T cells activated by
BM-DC contained very low levels of nitrite. Presence of pLN2 or
ex vivo TRC in this assay increased the NO2
2 concentration 2- and
5-fold, respectively (Fig. 5E), further strengthening the notion that
NO production by TRC leads to inhibition of T cell proliferation
or survival. In the case of ex vivo TRC approximately half of the
nitrite was due to iNOS activity in TRC as suggested by the use of
1400W or Inos2/2 TRC. They also suggest a contribution of NO
production by one of the two other NOS isoforms which are
insensitive to the concentrations of 1400W used and possibly
expressed in TRC or in the few endothelial cells found within the
adherent cell fraction. As the levels of iNOS protein correlate
better with NO-mediated inhibition of T cell expansion than those
of extracellular nitrite, the subsequent analysis was focused on the
factors inducing iNOS expression in TRC.
IFNc and other T cell derived cytokines induce iNOS
protein expression in TRC
To look at the role of T cells in inducing iNOS protein in TRC,
pLN2 were co-cultured with T cells and fixed cells analyzed for
intracellular iNOS protein by immunohistology. Non-activated T
cells induced iNOS in only a few TRC whereas T cells activated
with anti-CD3/CD28 beads up-regulated iNOS in a large
proportion of TRC (Fig. 6A). This suggests that most TRC have
the potential to express iNOS upon activation but typically only a
small proportion shows detectable protein. IFNc is a T cell-
derived cytokine known to induce iNOS expression in various cell
types [33,34,35,36]. Indeed, adding recombinant IFNc was
sufficient to induce iNOS expression in a fraction of pLN2
(Fig. 6A). Comparable results were obtained with ex vivo LN cells
when the adherent cells enriched for gp38+CD312 TRC were
used in presence of naı¨ve or activated T cells or IFNc (Fig. S4A).
Consistent with these data a significant increase in nitrite was
observed in the SN of TRC lines or ex vivo TRC upon IFNc
stimulation or upon addition of T cells with or without anti-CD3/
28 activation (Fig. S4B). To obtain a more quantitative assessment
of iNOS-expressing TRC, iNOS-expressing cells were measured
using intracellular staining and flow cytometry. This analysis
showed that while IFNc induced few TRC to become iNOS-
positive, there was a strong synergistic effect when both IFNc and
Figure 4. TRC dampen T cell proliferation by modifying both T cells as well as BM-DC. (A) Flow cytometric analysis of T cell proliferation
induced by anti-CD3/CD28 beads as based on CFSE dilution after 3 days of culture. WT T cells were cultured with beads and in presence of the pLN2
TRC line (T cell to TRC ratio of 100:1) or their absence (‘no stroma’). Representative histograms (top) show the percentage (6 standard deviation) of
divided CD8+ T cells and bar graphs (bottom) the absolute CD8+ T cell numbers per division. The bar graph (right) shows percentage of inhibition (as
in Fig. 1). Similar data were obtained for CD4+ T cells suggesting TRC may also suppress their expansion (data not shown). (B) Flow cytometric
analysis of cell proliferation induced by TRC-conditioned BM-DC. LPS-activated and SIINFEKL-pulsed BM-DC were co-cultured with pLN2 TRC at a ratio
of 1:1, or cultured alone. After overnight culture TRC-conditioned-BM-DC were re-isolated by MACS, counted and subsequently co-cultured for 3 days
with CFSE labeled OT-I cells mixed 1:50 with unspecific WT T cells (of which 50% are CFSE labeled). Representative histograms (top) show the
percentage (6 standard deviation) of divided OT-I cells and bar graphs (bottom) the absolute cell numbers per CFSE dilution peak. Percentage of
inhibition (as in Fig. 1) is shown in the bar graph on the right. (A,B) n = 3, (A) representative for$3 experiments, (B) representative for 2 experiments.
* P,0.05, ** P,0.01, *** P,0.001, if not indicated otherwise P-values are relative to ‘no stroma’.
doi:10.1371/journal.pone.0027618.g004
Lymph Node Fibroblasts Limit T Cell Expansion
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Figure 5. Suppression by TRC is mediated via NO and COX-1/2 dependant factors. (A,B,C) Flow cytometric analysis of the T cell activation
assay (as described in Fig. 1): (A) pLN2-TRC in the assay were present in the same well (‘normal’), separated by a permeable membrane (transwell) or
30% pLN2-TRC-conditioned-supernatant taken after 72 h from sub-confluent irradiated cultures was added to the cultures. The bar graph shows
percentage of inhibition. (B) Pharmacological inhibitors against iNOS (1400W, 1 mM) and/or Cox-1/2 (indomethacin, 10 mM) were added to the co-
cultures after optimization of their concentrations (tested range for 1400W: 1–10 mM; for indomethacin: 1–10 mM). The middle panel shows the
percentage of divided OT-I cells (6 standard deviation) and the bar graph (right) shows the percentage of inhibition. (C) T cell activation assay was
carried out in the presence of ex vivo isolated enriched TRC from WT or Inos2/2 mice along with the indicated inhibitors. The right panel shows the
percentage of divided OT-I cells (6 standard deviation) and the bar graph (middle) shows the percentage of inhibition. (D) Immunohistochemical
analysis of iNOS expression in pLN2 TRC lines. pLN2 cells were cultured alone (top) or in presence of OT-I and WT T cells together with LPS activated,
SIINFEKL-pulsed BM-DC (ratios as in Fig. 1) (bottom). Insets of higher resolution images are shown to indicate the generally increased iNOS expression
level in pLN2 co-cultured with BM-DC, antigen and T cells. (E) Bar graph showing NO2
2 levels in the co-culture supernatant from the T cell activation
assay shown in (b,c) as determined using a Griess assay. (A,B,C,E) n = 3, (D) n = 3–4, (A,C) representative for 2, (B) representative for$3 experiments,
(D) 1 experiment; * P,0.05, ** P,0.01, *** P,0.001, if not indicated otherwise P-values are relative ‘no stroma’.
doi:10.1371/journal.pone.0027618.g005
Lymph Node Fibroblasts Limit T Cell Expansion
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Figure 6. iNOS expression in TRC can be induced by IFNc. (A) Immunohistochemical analysis of iNOS expression in pLN2 TRC lines. pLN2 were
cultured for 2 days either alone (1st row), in the presence of WT T cells without (2nd row), with anti-CD3/28 beads (3rd row), or in the in the presence
of recombinant IFNc bottom row. The first column shows iNOS expression in red and nuclei stained with DAPI in blue, the second column shows
iNOS in red and gp38+ TRC in green. Tiny nuclei are from T cells, larger nuclei from BM-DC and pLN2. Scale bar: 50 mm. (B) Flow cytometric analysis of
intracellular iNOS expression in pLN2 TRC or BM-DC, cultured for 2 days either alone or together and with or without recombinant IFNc. The
histograms show the % of iNOS-expressing TRC (gp38+CD452CD312; upper panel) or BM-DC (CD45+; lower panel) (6 standard deviation). (C) NO2
2
concentration in the supernatant from the co-cultures shown in (b). (D) Quantitative RT-PCR analysis for Inos mRNA of pLN2 cells stimulated with
various cytokines or agonistic anti-LTbR (aLTbR) antibody for 7 h or 24 h. The expression levels relative to two housekeeping genes are shown.
Different symbols indicate different experiments. (A,D) n = 3–5, representative for 2 experiments. (B,C) n = 2, 1 experiment; * P,0.05, ** P,0.01,
*** P,0.001; if not indicated otherwise P-values are relative to ‘no stroma’.
doi:10.1371/journal.pone.0027618.g006
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BM-DC were present in the co-culture with up to 25% TRC being
positive (Fig. 6B). Given that BM-DC were occasionally observed
to express iNOS in the co-cultures, we assessed the influence of
IFNc and TRC on the ability of BM-DC to express iNOS.
Interestingly, both IFNc and TRC induced iNOS protein
expression in around 3% of BM-DC, but having both IFNc and
TRC in the co-culture led to a strong synergistic iNOS expression
in up to 30% of BM-DC (Fig. 6B). This synergy was reflected in
the almost 10-fold increase in extracellular nitrite levels detectable
in the SN (Fig. 6C). Interestingly, more than 50% of the nitrite
seemed to be due to iNOS expression in TRC rather than BM-DC
as assessed using Inos2/2 BM-DC. At present, a contribution by
the two other NOS isoforms to nitrite production can not be
excluded.
Next we analyzed the speed of iNOS induction in pLN2 by
looking at transcript levels. Already 7 h after IFNc stimulation Inos
mRNA was induced 10-fold and further increased after 24 h
indicating direct transcriptional regulation of the Inos promoter
(Fig. 6D). Interestingly, several pro-inflammatory cytokines (IFNa,
TNFa, LTa3) or LPS showed a similarly rapid and strong
induction of Inos transcripts while their maintenance at 24 h
differed. In summary, these results demonstrate that a subset of
both TRC and BM-DC can be triggered to express Inos transcripts
and proteins leading to the release of NO. Various pro-
inflammatory signals can serve as triggers in TRC, including
signals derived from newly primed T cells suggesting the possibility
of a negative feedback loop leading to inhibition of T cell
expansion in our in vitro co-culture assay.
Inos deficiency leads to exaggerated CD8+ T cell
responses in vivo
To characterize the expression of iNOS during immune
response in vivo, mice adoptively transferred with OT-I T cells
were immunized with OVA-expressing vesicular stomatitis virus
(VSV-OVA) and draining LN analyzed. By pressing LN across a
40 mm mesh a soluble fraction containing most hematopoietic cells
was obtained as well as a non-soluble stromal cell fraction,
including TRC and part of the DC [9,10]. Interestingly, one day
after immunization Inos transcripts were induced in both fractions
and dropped back to pre-immunization levels on day 2 and 4 (Fig.
S5A). These levels were always 5–10-fold higher in the fraction
enriched in stromal relative to hematopoietic cells. To identify
more precisely the cell type and frequency of iNOS expressing
cells in the draining LN intracellular iNOS protein expression was
analyzed by flow cytometry along with lineage markers. A subset
of at least 2.6% TRC were identified as major iNOS source
appearing on day 1 and being again undetectable on day 2 and 4
post infection (Fig. 7A). DC showed a weak induction of iNOS
expression on day 1 without reaching statistical significance
relative to day 0. Few macrophages (CD11b+ CD11c2) were also
found to express iNOS protein (data not shown). This result
emphasizes the inducible and transient activation of iNOS both at
the mRNA and protein level, consistent with pro-inflammatory
molecules inducing it. It also strengthens the notion of more than
one cell type expressing iNOS within the T zone of draining LN,
most notably TRC and DC. Our attempts to identify and localize
iNOS protein-expressing cells in situ were not successful (data not
shown), consistent with the low iNOS expression detected by flow
cytometry. As a next step the impact of Inos-deficiency on OVA-
specific T cell expansion and survival was measured in the LN
draining the site of VSV-OVA injection. While on day 4 after
immunization the total CD8+ T cell number was similar in both
mouse strains the percentage and number of OT-I T cells was 2-
fold higher in Inos2/2 relative to WT mice (Fig. 7B). On day 6 and
8 after immunization, the difference in OT-I T cell numbers was
minimal between the two strains presumably due to many effector
cells having left the LN between day 5 and 8. This scenario is
supported by the strong increase in OT-I cells in blood between
day 4 and 6 as well as by the significantly higher frequency of OT-
I cells in blood of Inos2/2 relative to WT mice (Fig. 7C). As a
consequence 2-fold more effector OT-I T cells accumulated within
day 8 spleen in Inos2/2 relative to WT mice (Fig. 7D).
Interestingly, the differentiation into effector cells occurred
efficiently in the absence of iNOS, as based on the analysis of
IFNc expression and in vitro killing activity of effector CD8+ T cells
from LN and spleen (Fig. S5 B,C). To address whether iNOS
expression is critical in hematopoietic or non-hematopoietic cells
bone marrow chimeras were generated. Unfortunately, a cell
trapping defect was observed in inflamed LN if the stromal cell
compartment was Inos-deficient, presumably due to a role of NO
in vasodilation in irradiated mice but not straight Inos2/2 mice
(Fig. S6). Therefore, no conclusions could be drawn from these
experiments. In summary, the in vivo data indicate that acute
inflammation associated with a viral infection leads to the transient
expression of NO by TRC and DC found within the LN T zone,
which slows down and lowers the antigen-specific T cell expansion
but does not seem to impact on the differentiation and migration
of effector T cells.
Discussion
Inflamed LN as well as the TRC network are generally
considered as strongly immune-stimulatory for T cell immunity.
Surprisingly, we obtained several lines of evidence demonstrating
an inhibitory role of TRC in early T cell activation: 1) In vitro TRC
limit the expansion of CD8+ T cells primed by antigen-pulsed BM-
DC or anti-CD3/28 beads at TRC-T cell ratio’s as low as 1:100
with T cell effector function being reduced as well. 2) TRC reduce
the T cell activation potential of antigen-loaded BM-DC. 3) TRC
constitutively express transcripts for Cox-2, the enzyme required
for the synthesis of PGE2 and related factors [37]. Inhibition of
Cox-1/2 markedly reduces this suppressive effect. 4) When
exposed to pro-inflammatory cytokines pLN2 and ex vivo TRC
transiently express iNOS protein leading to NO2
2 synthesis. This
correlates with rapid induction of Inos transcripts in activated
pLN2. Inhibition of iNOS or use of Inos-deficient TRC markedly
reduces the suppression with this effect being enhanced by a Cox-
2-inhibitor. 5) Upon immunization, iNOS protein gets transiently
expressed in TRC and DC within the draining LN. 6) Absence of
iNOS in vivo correlates with an exaggerated primary CD8+ T cell
response, consistent with the previous observation of an exagger-
ated memory T cell response in Inos2/2 mice [38]. Thus, while
TRC may have several ways of enhancing T cell activation, our
assays have only revealed attenuating effects.
Attenuating effects of TRC on T cell immunity have been
reported recently based on the expression of self-antigen in the
context of MHC I as well as PD-L1 expression on TRC leading to
modulation of CD8+ T cell responses [19,20,21]. Here we have
used fibroblasts of the LN T zone to show that they are a source of
soluble immunomodulators such as NO and COX-1/2 dependent
factors strongly inhibiting T cell expansion in response to a foreign
antigen, with no role observed for PD-L1. Another study had
noted iNOS expression in reticular LN fibroblasts upon infection
with Leishmania major parasites, but the precise nature and
localization of these cells have remained unclear. In addition,
NO was in that case shown to be important for the control of the
parasite rather than for adaptive immunity [34]. Together these
data suggest TRC may help control CD8+ T cell responses to both
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self- and foreign-antigens. Whether they also modulate the
deletion of self-reactive T cells still needs to be tested.
Two previous reports have highlighted the capacity of spleen-
derived stromal cells in inhibiting T cell activation. A mix of
adherent stromal cells, possibly including TRC, was shown to
promote development of BM-derived progenitor cells into IL-10+
regulatory DC [25] or the conversion of mature BM-DC into NO+
regulatory DC [24]. We did not observe consistent changes in the
surface phenotype of TRC-conditioned DC, possibly because our
co-cultures were less than 16 h allowing only short-term changes.
In contrast, the previous reports were based on co-cultures of 1–2
weeks allowing developmental changes. While we have not yet
identified the reason for the decreased stimulatory capacity of
TRC-conditioned DC it may be due to the rapid induction of
iNOS in BM-DC.
Our results are reminiscent of observations with MSC known to
modulate many aspects of innate and adaptive immunity,
including T cell proliferation [30,31]. In vitro BM-derived MSC
were shown to block mitogen- and DC-induced T cell prolifer-
ation by many different pathways, including NO and PGE2
production [36,39,40]. In settings of allografts and autoimmune
disease large numbers of injected MSC strongly suppress T cell
responses due to their anti-inflammatory properties, and due to
their efficient homing to inflammatory sites and lymphoid tissues
[30,31,41]. Interestingly, mature mesenchymal cells such as
fibroblasts from various non-lymphoid tissues also dampen T cell
expansion [27,28,29,31] suggesting mesenchymal cells at several
maturation stages share this property. Alternatively, MSC and
fibroblasts may be hard to distinguish [28]. We propose that LN
and spleen TRC have conserved this immunosuppressive property
that they share with MSC and fibroblasts from non-lymphoid
tissues. The extent of inhibition was highly dependent on the
number of TRC being present in the culture (unpublished
observation) which may explain the difference in the extent of
NO-mediated suppression observed in vitro versus in vivo. Our
preliminary results suggest that this inhibitory effect not only
affects CD8+ but also CD4+ T cells. Besides affecting T cell
expansion and possibly apoptosis, TRC presence partially reduced
T cell effector differentiation in vitro but not in vivo. While the
reason for this difference is not known, it may be explained by the
presence of lower NO concentrations or additional factors found in
vivo that positively influence CD8+ T cell differentiation. Given
Figure 7. Lack of iNOS in vivo leads to increased an primary T cell response after viral infection. (A–D) WT or Inos2/2 mice were retro-
orbitally grafted with 100’000 splenocytes from OT-I transgenic mice one day prior to subcutaneous infection with VSV-OVA. Draining pLN, blood or
spleen from infected mice were harvested at the indicated time points after infection and cell suspensions generated by using collagenase digestion
(A) or by mechanical homogenization (B, D). (A) Intracellular iNOS protein expression in TRC (gp38+CD452CD312CD352) or DC
(CD11c+MHCII+CD45+) as analyzed by intracellular flow cytometry. Representative histograms show the percentage (6 standard deviation) of
iNOS expressing TRC (top) and DC (bottom) in WT versus Inos2/2 mice. (B) The graph on the left side shows the total CD8+ T cell numbers, the graph
in the middle the percentage of OT-I T cells among the CD8+ T cells and the graph on the right side the total OT-I number in pLN (pool of 6 draining
LN). No significant difference was observed in total LN cell numbers between immunized WT and Inos2/2 mice (not shown). (C) Shows the
percentage of OT-I T cells among the CD8+ T cells in the blood, (D) shows the total number of OT-I T cells in the spleen. (A–D) n$3, 1 out of 2
independent experiments is shown. * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0027618.g007
Lymph Node Fibroblasts Limit T Cell Expansion
PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e27618
that TRC and non-lymphoid fibroblasts can be grown easily from
many accessible tissues in humans, such as tonsils or skin, they may
represent an interesting source of immunomodulatory cells. A very
recent study using skin fibroblasts has established their potential in
efficiently suppressing the clinical signs of experimental arthritis in
mice [29].
Different mechanisms of suppression have been described for
MSC: they can either directly inhibit T cell activation or reduce
the stimulatory capacity of DC by using several pathways [30,31].
MSC can produce high amounts of NO upon contact with T cells,
which interferes with STAT-5 phosphorylation and therefore IL-2
signaling [42]. MSC-mediated T cell suppression could be
partially neutralized using inhibitors of iNOS or Cox-2, or using
Inos2/2 MSC [36,40] thus showing clear parallels in MSC- and
TRC-mediated T cell mechanisms. In our in vitro experiments we
have obtained evidence for an additive inhibitory effect of NO and
COX-1/2-dependent factors (possibly PGE2), but additional
factor(s) probably remain to be identified to explain the entire
inhibitory effect. Blocking TGFb, PD-L1, IL-10, arginase-1 and
IDO activity did not influence TRC mediated inhibition, however,
additional studies will be necessary to fully rule out their
contribution. Furthermore, we cannot exclude that the other
two NOS isoforms, eNOS and nNOS, are expressed in TRC and
contribute to the TRC mediated inhibition.
The expression and activity of iNOS is tightly controlled at
several levels with the best-characterized positive regulators being
IFNc IFNab, TNFa IL-1 and LPS [35]. Indeed, iNOS
expression in TRC was induced by all of these pro-inflammatory
cytokines confirming and extending previous data using LN
fibroblasts, MEF and MSC [33,34,35,36]. Interestingly, only a
subset of IFNc-stimulated TRC expressed iNOS, even when a
TRC clone was used (data not shown), in line with previous
reports on other fibroblast types [33,34] as well as our
observation on BM-DC reported here. Recent results suggest
that IFNc is not restricted to immune synapses but more widely
accessible throughout the T zone [43] which may explain why
TRC obtain this signal in the absence of cognate interaction with
primed T cells. Several reports showed that IFNc during T cell
priming influences the degree of CD8+ T cell contraction
(reviewed in [44]). While IFNc signaling within T cells may lead
to this outcome [44], our results suggest that IFNc-signalling in
TRC and DC leading to NO production early after infection
might not only control the expansion, but also the contraction
phase of CD8+ T cells, such as by nitrosylating and thereby
altering key proteins of the IL-2 or TCR signaling pathway
[42,45]. More experiments will be necessary to test this
hypothesis and to understand the underlying mechanism.
Strikingly, iNOS induction and NO2
2 production was highest
when TRC, activated DC and IFNc were present together
suggesting only adjacent TRC become licensed to suppress T cell
expansion with this being a highly controlled and transient
process. The DC-derived signals leading to iNOS expression in
TRC remain to be identified. Good candidates are IL-1a/b and
TNFa which may act synergistically with IFNc, similar to iNOS
expression in MSC [36]. NO effects are known to be highly dose-
dependent. Low NO doses can enhance T cell proliferation, as
possibly suggested by the decreased T cell expansion in some of
the BM chimera experiments (Inos2/2 into wt). Higher NO doses
are known to induce cell-cycle arrest and apoptosis of T cells
[35,46] indicating that the reduced expansion seen in presence of
TRC may represent a combined effect of reduced proliferation
and increased apoptosis of T cells. The dual role of NO may also
explain the only two-fold higher expansion of T cells in the
absence of iNOS. Given that NO is a highly reactive gas close
proximity to TRC is likely to be critical in inhibiting T cell and
DC activation. To further improve this process cytokine-
stimulated TRC could actively recruit or retain primed T cells,
as suggested for MSC [36]. Interestingly, TNFa-stimulated TRC
were shown to express the IFNc-inducible chemokine CXCL10
that attracts activated but not naı¨ve T cells [47].
Both in vitro and in vivo, we found not only TRC but also DC to
express iNOS and produce NO. It is possible that the iNOS+ DC
subset identified in vivo represents the inflammatory TipDC
(TNFa+iNOS+CCR2+) which are recruited into the splenic T
zone early during infection with Listeria monocytogenes [48] or other
pathogens [49] as they were also CD11cint in our analysis
(unpublished observation). Interestingly, increased T cell prolifer-
ation was also reported for Ccr22/2 mice lacking TipDC [48]. In
vitro we found iNOS expression in BM-DC to be induced in a
synergistic manner by IFNc and TRC presence, similar to
synergistic effects of IFNc and BM-DC on iNOS expression by
TRC. While the factors involved in the cellular crosstalk remain to
be identified these findings point to the interdependence of these
two cell types in inhibition of T cell expansion, an observation
which needs further in vivo studies with cell-type specific Inos
deletion. Based on our current results we propose the following
working model (Fig. S7): Low levels of iNOS expression are
induced in both immigrating DC and TRC when they meet in the
T zone early during the immune response. This may increase the
threshold required for T cell priming and thereby prevent the
activation of low-affinity T cells that are often self-reactive. Once
the first T cells are primed and produce IFNc they may boost
iNOS expression in both cell types in a transient fashion thereby
inducing a negative feedback loop dampening T cell expansion by
either slowing down their proliferation or diminishing their
survival.
The immunosuppressive feature of mesenchymal cells is
intriguing. It raises the question of why these cells have this
function, especially when considering TRC localize to the T zone
of SLO where inhibitory effects are less expected but well known
from TipDC and regulatory T cells. We would like to propose two
possible reasons: 1) Keeping the LN in a slightly suppressive state
might be a mechanism to limit the activation of potentially auto-
reactive cells while allowing strong immune responses to foreign
antigens to occur. In line with this hypothesis we found Cox2
transcripts to be highly expressed in naı¨ve LN. Others showed that
high iNOS and NO2
2 levels are frequently associated with
autoimmune disease and Th1-mediated inflammation [35,46].
Consistent with a protective role of this pathway in certain
autoimmune diseases, Inos2/2 and Ifng2/2 mice have a higher
incidence, increased severity and less relapses of experimental
autoimmune encephalitis that correlate with increased prolifera-
tion of auto-reactive T cells relative to WT mice [50,51]. Similarly,
in a mouse model for myasthenia gravis Inos2/2 mice develop
more self-reactive T and B cells, including epitope spreading [52].
2) In contrast to recirculating hematopoietic cells fibroblasts
resident in lymphoid and non-lymphoid organs have a function for
the organ itself: ensure its integrity and functionality. During
injury, such as infection or inflammation, fibroblasts perform tissue
repair to reestablish homeostasis. LN swelling during immune
response can be viewed as a threat to the organ as it is
characterized by the dramatic increase in organ size due to the
influx of many naı¨ve lymphocytes as well as the rapid expansion of
antigen-specific lymphocytes. The strong increase in lymphocyte
numbers within the T zone may be harmful for the existing TRC
network that functions as the structural platform for T cell priming
and probably also T cell differentiation. Destruction of the TRC
architecture, such as after LCMV infection, correlates well with
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immunodeficiency [6,32,53]. Limiting T cell expansion early in
the immune response might be necessary to give TRC the time to
adjust step-wise to the new space demands and to start
proliferating thereby increasing the scaffold size accommodating
T cells and DC. Such a process may ensure continuous
functionality of the growing organ which is finally also to the
benefit of efficient effector T cell generation.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the Swiss
act for animal welfare. All mouse experiments, including the
protocols, were authorized by the Swiss Federal Veterinary Office
(Bern, Switzerland) with permits issued to S.A.L. (number 1612.2),
B.J.M. (number 2216) and D.Z. (number 2308). All efforts were
made to minimize suffering.
Mice and immunizations
Mice used were C57BL/6 (B6, CD45.2+); Janvier), B6 OT-I
CD45.1+, Ubiquitin-gfp transgenic and Inos2/2 (Jackson laborato-
ries). For immunization mice were subcutaneously injected at six
sites in the back to target six pLN. 25 mg NP-CGG (Biosearch
Technology) was diluted in Montanide ISA 25 (25% in PBS;
Seppic). Alternatively, 0.336106 pfu VSV-OVA [54] were
injected after retro-orbitally grafting 0.16106 OT-I splenocytes.
Bone marrow (BM)-chimeras: BM from donor-mice was obtained
from femur and tibia by crushing bones with a mortar. 156106
BM cells were injected retro-orbitally into recipient mice
irradiated twice with 450 rad in a 4 h interval. The following 4
weeks mice received the antibiotic ‘Baytril 10%’ (1/1000) in the
drinking water. WT mice used were either CD45.2+ or Cd45.1+
while Inos2/2 mice were CD45.1+. All mice were maintained in
specific pathogen-free conditions.
Flow cytometry
0.1–26106 cells were blocked (2% normal-mouse-serum
(Sigma) or anti-CD16/32 antibody (2.4G2) and then stained with
antibodies (see table S1) on ice. Dead cells were excluded using 7-
AAD (7-Aminoactinomycin-D) or DAPI (4,6-diamidino-2-pheny-
lindole), or Aqua (all from Invitrogen) in case of fixed cells.
Intracellular staining: Cells were fixed with 4% PFA, pemeabilized
using 0.1% saponin (Sigma) and incubated with anti-IFNc
(XMG1.2) (45 min) or anti-iNOS antibody (rabbit antibody;
Millipore) followed by Alexa488-coupled donkey-anti-rabbit IgG
(Molecular Probes) (30 min each). For IFNc staining: cells were re-
stimulated in vitro with 1 mM SIINFEKL peptide in the presence of
Brefeldin-A (10 mg/ml, AppliChem) for 3–4 h at 37uC. Data were
acquired on a FACSCanto or LSR II flow cytometer (both
BectonDickinson) and were analyzed with FlowJo software
(TreeStar).
Ex vivo stromal cell isolation
LN from CO2-killed mice were dissected, their capsule opened
with a 26-gauge needle and the organs digested for 30 min at
37uC in DMEM (Invitrogen) containing collagenase IV (3 mg/ml;
Worthington), DNAse-I (40 mg/ml; Roche), 2.5% FCS and
1.2 mM CaCl2, 10 mM HEPES and 50 IU/ml Penicillin,
50 mg/ml streptomycin. Subsequently, EDTA was added (5 mM
final) and remaining clumps dissolved by pipetting, passed through
a 40-mm mesh and re-suspended in complete RPMI containing
10% FCS. For cell isolation from femoral muscle, kidney and
heart, the respective organs were dissected, cut into small pieces
and digested as described above for 1 h at 37uC. Cell isolation
from ears: Ears were split with forceps and digested in 0.5%
trypsin (Sigma) and 5 mM EDTA for 20 min at 37uC to separate
dermal and epidermal sheets. These were cut into small pieces and
digested for 2 h as described. After digestion stromal cells were
enriched by panning using antibodies against CD45 (M1/9.4.3),
CD31 (GC-51), CD11c (N418) and CD11b (M1/70). Cells were
counted using trypan blue dye and an automated cell counter
(Countess, Invitrogen).
Cell lines and bone-marrow-derived dendritic cells (BM-
DC)
Stromal cells were isolated as described above from various
tissues of naı¨ve B6 or Ubiquitin-gfp B6 mice. After overnight culture
in complete RPMI non-adherent cells were washed away.
Adherent cells were cultured until confluent, then split on new
dishes. Cells were used between passage 5 and 25. Other B6-
derived cell lines used: B16-F10 and MC-38 tumor lines (kindly
provided by A.Donda, Lausanne) [55], spleen and lung fibroblasts
(C.Buckley [26]), MEF (M.Heikenwalder, Munich) and MSC
(P.Nelson, Munich [56]). B6 BM-DC were generated as previously
described [57].
T cell activation assay
Stromal cells: Per 24-well 16104 stromal cells from lines were
seeded in complete RPMI and after overnight culture irradiated
with 1000rad. Initially, experiments with non-irradiated or
irradiated pLN2 were performed with no difference in the
outcome (data not shown). Ex vivo stromal cells were isolated as
described above and non-adherent cells washed away after
overnight culture (density comparable with lines); they were non-
proliferative and therefore not irradiated. BMDC: They were
activated with 0.5 mg/ml LPS (Sigma) for 6 h at 37uC. 2 h after
LPS addition 1 mM SIINFEKL peptide was added. 16104 BM-
DC were added per 24-well. T cells: They were obtained ex vivo
from spleen and pLN dissected from CO2-killed WT B6 and OT-I
transgenic mice and suspended by meshing. Erythrocytes were
removed using red blood cell lysis buffer (Tris-Ammonium
chloride based). CD8 cells were enriched by panning using
antibodies to B220 (RA3-6B2), CD4 (H129.19.6), CD11b (M1/70)
and CD11c (N418). OT-I cells were labeled with 2 mM CFSE
(Invitrogen). Only 50% of WT B6 T cells were CFSE-labeled to
identify the peak of undivided cells, with the 50% unlabeled T cells
showing the background fluorescence of T cells. Per 24-well
0.046106 CFSE+ OT-I cells together with 0.986106 unlabeled B6
WT cells and 0.986106 CFSE+ B6 WT cells were added. The
assay was performed in complete RPMI enriched with 16MEM
(Invitrogen), 3 ng/ml murine IL-7 (Peprotech) and 10 U/ml
human IL-2 (Merck Serono). After 2–4 days, cells were harvested,
counted and analyzed by flow cytometry. Transwell assays used
were 0.4 mm transwell chambers (HTS 24-well, Vitaris). Blocking
experiments used 10 mM indomethacin (Sigma), 1 mM 1400W
(= dihydrochloride; Sigma), 10 mM 1-Methyl-L-tryptophan (1-
MT; Sigma), 200 mM (S)-(2-Boronoethyl)-L-cysteine (BEC, Cal-
biochem), 10 mg/ml anti-PD-L1 (MIH5, eBioscience), 20 mg/ml
anti-IL-10 (kind gift from F.Tacchini, Lausanne, Switzerland) or
30 mg/ml anti-TGFb (clone 1D11.16.8; BioXCell). To better
compare the decrease of T cell proliferation between experiments
the attenuating effect by the stromal cells was defined as percent
inhibition in divided OT-I T cell numbers relative to the ‘no
stroma’ control: {1-(number of proliferated cells)stroma/(number of
proliferated cells)no stroma}*100). The ‘no stroma’ control was
considered as 0% inhibition; absence of proliferating OT-I cells
was considered as 100% inhibition.
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T cell activation by anti-CD3 and anti-28 beads
2500 stromal cells were seeded per 96-well and after overnight
culture irradiated with 1000 rad. 2.56105 T cells mixed with
1.256105 anti-CD3/28 beads (Dynabeads, Invitrogen) were
added. After 2–3 days of co-culture cells were harvested by gentle
pipetting. Live cells were counted and analyzed by flow cytometry.
T cell activation by TRC-conditioned BM-DC
10’000 stromal cells were seeded per 24-well and after overnight
culture 10’000 LPS-activated and SIINFEKL-pulsed BM-DC
were added. After overnight culture BM-DC were separated by
magnetic cell sorting (MACS): Cells were stained with biotinylated
anti-gp38-antibody (clone 8.1.1) followed by streptavidin-coupled
magnetic beads (Miltenyi). Cells were separated using MS-
columns (Miltenyi) according to the manufactures instructions.
Per 96-well 2500 TRC-conditioned-DC were co-cultured with
0.016106 CFSE labeled OT-I cells mixed with 0.486106
unspecific WT T cells for 3 days.
T cell activation and cytokine stimulation of stromal cells
in chamber slides
3000 stromal cells were seeded per well in 8-well chamber slides
(Falcon) and cultured overnight. T cell activation: 0.256106 WT
T cells and 0.1256106 anti-CD3/28 beads were added or 5000
CFSE-labeled OT-I T cells mixed with 0.2456106 WT T cells
together with 5000 LPS-activated and SIINFEKL-pulsed BM-DC.
Cytokine stimulation: IFNc IL-1b, TNFa, LTa3 (all 10 ng/ml,
from Peprotech), 500 U/ml IFNa (PBL, Interferon source) or the
agonistic antibody against LTbR (4H8 WH2; provided by
C.Ware) were added to stromal cells for 7 h or 24 h.
In vitro cytotoxicity assay
Target cells (T): WT splenocytes were labeled with 0.16 mM or
0.5 mM eFluor670 (eBioscience). The eFluro670high population was
pulsed with 1 mM SIINFEKL for 1 h at 37uC. Per 96-well 5000
eFluor670high and 5000 eFluor670low cells were added. Effector cells
(E) were harvested from the T cell activation assay on day 4 or from
spleen or pLN from VSV-infected mice. Cells were mixed in
different E/T ratios and after overnight culture analyzed by flow
cytometry. Alternatively, they were isolated from homogenized
spleen or pLN fromVSV-infected mice. Effector cells were added to
target cells in different ratios and incubated overnight. The ratio of
target cells was analyzed by flow cytometry, as were the input
numbers of OT-1 effector T cells allowing the calculation of the
effective E/T ratio. Percentage specific lysis = {12(specific survi-
val)sample/(specific survival)control}*100 with specific survival = e-
Fluor670high/eFluorlow, (control: target cells only).
Nitrite detection
NO2
2 in cell culture supernatants was measured using the
Griess assay. 0.1% N-1-naphtylethylenediamine dihydrochloride
(Sigma) was mixed with p-aminobenzensulfonamide (Sigma) in
5%phosphoric acid; 100 ml of this mixture were incubated with
100 ml cell culture supernatant. After 10 min incubation at RT
absorbance was measured at 550 nm and background absorbance
at 690 nm was subtracted as well as the absorbance of complete
RPMI. In each measurement a NO2
2 -standard series (100-
0.1 mM NaNO2; Sigma) was included.
Immunofluorescence microscopy
Staining and microscopy of cryosections were performed as
previously described [9]. Cells cultured in chamber slides: chambers
were removed according to the manufactures description, staining
and microscopy was performed as done for cryosections (for
antibodies used see table S2). Images were acquired with a Zeiss
Axioplan microscope at RT and treated with ImageJ (http://
rsbweb.nih.gov/ij/) and Photoshop software (Adobe).
Transcript analysis
RNA isolation reverse transcription and quantitative real-time
PCR was performed as described [9]. For additional primers used
see table S3. Efficiency-corrected expression of Inos, Cox2, Ccl19
and Ccl21 was normalized by dividing with the geometric mean of
expression of two housekeeping genes.
Statistical analysis
F-test was performed to determine usage of equal or unequal
variance in the t-test, with P,0.05 considered as unequal variance.
Statistical significance was determined with students t-test.
Supporting Information
Figure S1 Surface phenotype of TRC lines and ex vivo
isolated TRC. Flow cytometric analysis of the surface phenotype
of TRC lines (A) or TRC isolated ex vivo from pLN (B) used in the
T cell activation assay shown in Figure 1. (A) The first row shows
dot plots of CD31 versus CD45 expression and the percentage of
CD452 CD312 cells. (6 standard deviation). Following rows show
histograms with the indicated surface markers on cells pregated on
CD452 CD312 cells. pLN2 and pLN1 are two different TRC
lines derived from pLN-pools derived from distinct mice. pLN2
cells also express CD54 (ICAM-1), CD140b (PDGF-Rb) and
CD105 (Endoglin) (not shown). (B) CD452 CD312 cells were
analyzed in dot plots for CD31 versus gp38 expression (first row).
The following rows show the indicted surface markers on CD452
CD312 CD352 gp38+ cells (lower quadrant on the right in the
gp38 versus CD31 dot plot; displayed as black line). Grey
shadowed curves show the ‘no primary antibody’ control. (A,B)
representative for $3 independent experiments.
(TIF)
Figure S2 Surface phenotype of non-lymphoid cell lines
and ex vivo isolated stromal cells. Flow cytometric analysis
of the surface phenotype of (A) non-lymphoid cell lines or (B) ex vivo
stromal cells isolated from dermis, epidermis and kidney, and used
in the T cell activation assay shown in Figure 3. (A) The first row
shows dot plots of CD31 versus CD45 expression on the cell lines,
the following rows show histograms with the indicted surface
markers on CD452 CD312 cells. (B) CD452 CD352 cells were
analyzed in dot plots for CD31 versus gp38 expression (first row).
The following rows show histograms with the indicated surface
markers on CD452 CD352 CD312 gp38+ cells as black line, and
gp382 CD312 cells as dotted line (includes epithelial cells. Grey
shadowed curves show the ‘no primary antibody‘ control. (A,B)
representative for 2–3 independent experiments.
(TIF)
Figure S3 Suppression of T cell proliferation by TRC is
not mediated by IDO, PD-L1, TGFb, IL-10 or arginase-1.
Flow cytometric analysis of the T cell activation assay (as described
in Fig. 1) in the presence of pharmacological inhibitors of IDO
(10 mM 1-MT), arginase-1 (200 mM BEC) or blocking antibodies
against PD-L1 (10 mg/ml), TGFb (30 mg/ml) or IL-10 (20 mg/ml).
One out of several tested inhibitor concentrations is shown along
with the percentage of inhibition (as in Fig. 1). The dotted line
shows the average inhibition by pLN2 TRC without inhibitor/
blocking antibodies. n$3, representative for 2–3 experiments.
(TIF)
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Figure S4 IFNc induces iNOS expression and NO
production in ex vivo TRC, while stimulation of pLN2
with different cytokines does not induce Cox2, Ccl21 or
Ccl19 transcription. (A) Immunohistological analysis of iNOS
protein expression in ex vivo TRC. TRC-enriched cells from pLN
of WT mice were cultured for 2 days either alone (top row), in the
presence of WT T cells without (second row) or with anti-CD3/28
beds (third row) or in presence of 10 ng/ml recombinant IFNc
(last two rows). For the first four rows the first column shows iNOS
expression (red) and DAPI+ nuclei (blue), while for the last row,
the first column show the ‘no primary antibody control’ (red), the
second column shows gp38+ CD312 TRC and gp38+ CD31+
lymphatic cells. Arrows show examples of gp38+ CD312 TRC
expressing iNOS. Scale bar: 50 mm. (B) Analysis of NO22
concentration in the supernatants from the co-cultures shown in
(A). (C) Quantitative RT-PCR analysis of Cox2, CCl21 and CCl19
mRNA levels in pLN2 stimulated with various cytokines or
agonistic antibody to LTbR (aLTbR) for 7 h or 24 h. The relative
expression levels are shown. Different symbols indicate different
experiments. (A–C) n = 3–4, (A–C) respresentative for 1–2
experiments. * p,0.05,**p,0.0,***p,0.001, p values are relative
to unstimulated pLN2.
(TIF)
Figure S5 Inos expression and CD8+ T cell effector
functions in VSV-OVA infected WT or Inos2/2 mice. WT
or Inos2/2 mice were retro-orbitally grafted with 100’000
splenocytes from OT-I transgenic mice one day prior to
subcutaneous infection with VSV-OVA. (A) Regional pLN from
infected mice were harvested 1, 2 or 4 days after infection and
analyzed for Inos mRNA by by quantitative real time-PCR on
crude fractions of LN. Normalized Inos mRNA levels are shown.
(B, C) Draining pLN and spleen were harvested on day 4 and 6
after infection, homogenized and analyzed for intracellular IFNc
protein expression in OT-I T cells using flow cytometry (B) or for
killing activity (C). (B) Histograms show the percentage of OT-I T
cells (6 standard deviation) expressing IFNc. Bar graphs show the
median fluorescence intensity of the IFNc staining within OT-I T
cells. (C) Cells from day 6 were used in an in vitro killing assay. The
specific lysis of target cells is shown for the respective effector to
target ratios. (A–C) n = 3 (A,B) representative for 2 experiments,
(C) 1 experiment (similiar data were obtained for day 8 LN and
spleen, not shown).
(TIF)
Figure S6 Bone marrow chimeras lacking Inos in the
non-hematopoietic system show a trapping defect in
immunized lymph nodes. To assess the relative contribution
of hematopoietic versus non-hematopoietic cells as iNOS source,
BM chimeras were generated having Inos-deficiency in either the
hematopoietic system (Inos2/2 BM into WT hosts) or non-
hematopoietic system (WT in Inos2/2 and were compared with
control chimeras (WT into WT). 2 months after reconstitution,
BM-chimeras were infected with VSV-OVA (as described in
Figure 7) and 4 days after infection pLN were collected, single cell
suspensions counted and stained before analysis using flow
cytometry. As comparison non-immunized BM-chimeras are
shown. Inos2/2 into Inos2/2 chimeras have not been made.
Surprisingly, none of the chimeras showed an increased OT-I
expansion. Rather, Inos -deficiency in either the hematopoietic or
the non-hematopoietic system led to a strong decreased OT-I
expansion. Surprisingly, lymphocyte trapping did not occur in the
case of Inos -deficiency in the non-hematopoietic compartment, in
contrast to the other two groups and the non-chimeric Inos2/2
mice (Figure 7). Therefore, the expansion of OT-I T cells cannot
be interpreted for that group of mice. The lack of OT-I expansion
in the group of mice having Inos deleted in the hematopoietic
system indicates also a positive role of Inos in T cell proliferation,
presumably in a low but not high concentration, as previously
suggested [46]. In all BM chimeras the chimerism was .85% as
assessed by measuring ratio’s of CD45.2 (WT) versus CD45.1
(Inos2/2 or WT) expression on total LN cells using flow cytometry.
2–4 mice were in each group.
(TIF)
Figure S7 Model showing how inflammatory cytokines
may induce iNOS expression in TRC and create a
negative feedback loop limiting antigen-specific T cell
expansion. During the early phase of immune response antigen-
specific CD8+ T cells interact with antigen-bearing DC within the
context of the TRC network within the T zone of the draining LN.
Upon prolonged cognate interaction T cells start to produce IFNc
and possibly other cytokines that induce strong but transient iNOS
expression in neighboring TRC as well as DC. The local production
of NO creates a negative feedback loop in which NO and possibly
other inhibitory factors limit the expansion of neighboring antigen-
specific T cells. This effect is due in part to direct inhibition of T cell
proliferation or survival, in part to a decrease in the stimulatory
capacity of DC. NO is known to lead to nitrosylation of cysteine-
and tyrosine-containing proteins thereby altering their function,
including in T cells where reduced T cell proliferation was reported
in presence of NO [35]. High NO concentrations may also reduce
T cell survival. An alternative model is that in vivo innate immune
cells, such as NK cells, become activated early during the response
and release IFNc that induces iNOS in TRC and DC. Together,
these processes may prevent overshooting antigen-specific T cell
expansion while affecting much less T cell differentiation. This
selective negative regulation of T cell numbers by TRC and DC
may allow gradual organ and stromal cell growth thereby achieving
a compromise between preservation of functional organ structure
and fast effector T cell differentiation. It is reminiscent of the role of
TRC in controlling naı¨ve T cell numbers [9,13]. The early and
transient induction of iNOS may have also an impact on later
aspects of the immune response, such as the contraction phase and
memory T cell generation, as they are thought to be controlled by
the conditions encountered during the T cell priming phase [1,44].
(TIF)
Table S1 Staining reagents used for flow cytometry.
(DOCX)
Table S2 Staining reagents used for immunofluores-
cence microscopy.
(DOCX)
Table S3 Primer sequences for quantitative PCR anal-
ysis.
(DOCX)
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